INTRODUCTION
Already in 1896 Beatson (1) acknowledged, in his famous article on the effect of oophorectomy in breast cancer treatment, that young women seemed to have ap oor prognosis. Although today it is generally accepted that young women have an inferior prognosis compared to middle-aged women, it is controversial whether young age at diagnosis is an independent negative prognostic factor, or whether young age is just associated with ag enerally worse profile of prognostic factors. Furthermore it is debated whether the negative effect of young age can be modified by chemotherapy.
PROGNOSTIC EFFECT OF AGE AT DIAGNOSIS
Previously, older patients with breast cancer were assumed to have am ore favourable course than younger women, but this view is no longer held (2, 3).
Different approaches have been used to investigate this subject. The largest studies are population-based using register information (2, 3). Women at the age of 40 to 55 years have been found to have the best prognosis. Hereafter, the prognosis deteriorates with increasing age. Furthermore, studies have concluded that younger patients less than 35 years of age do worse than middle-aged women. Patients less than 35 years constitute about 2%of the total population of breast cancer patients (2, 3). Some studies fail to identify the group of young high-risk patients, presumablybecause thecut offpoint of youngage is set higher than 40 years. In such studies the small number of patients less than 35 years are mixed with amuchlargergroup of middle-agedpatientswitha relatively good prognosis. The advantage of the large studies, based on up to around half am illion patients, is the great statistical power. The limitation is that such studies include no or minor information on e.g. stage of disease, and therefore offer ar ather crude analysis of the effect of age at diagnosis. Table 1p resents larger studies on the prognostic effect of young age at diagnosis based on clinical materials published after 1990. These studies generally find young patients to have ap oor profile of prognostic factors compared to women over 40 years of age. In particular, young patients have ah igher possibility of lymph node involvement, higher grades of anaplasia, and ah igh risk of tumours being oestrogen receptor negative. On this basis alone, young patients would be expected to have an impaired survival. However, when adjusting for the most common prognostic factors (tumour size, lymph-node status, grade of malignancy, oestrogen receptor status) in the analysis of disease-free and overall survival, the majority of studies conclude that young age remains an independent negative prognostic factor (Table 1) . On the other hand some au- thors claim that young age alone serves as as urrogate for an increased frequency of adverse prognostic factors, and that young age alone confers no independent risk on the women.
BENEFIT OF ADJUVANT SYSTEMIC TREATMENT
The Danish Breast Cancer Cooperative Group, DBCG, has since 1977 conducted nation-wide prospective studies on breast cancer treatment and survival among Danish women with primary breast cancer. Primary clinical and histopathological data concerning surgical treatment, postoperative treatment, and status at follow-up visits have been registered by the DBCG data base using specific case report forms submitted by departments of surgery, pathology and oncology in Denmark. In apopulation-based study (8) survival patterns were analysed among 9,541 women less than fifty years of age at the time of diagnosis. This study took advantage of the unique longitudinal registration of Danish breast cancer patients registered in the DBCG data base including information on classical prognostic factors. Table 2shows the relative risk of dying during the first ten years after diagnosis after adjustment for the indicated prognostic factors. As it appears, women less than forty years of age at diagnosis had asignificantly increased risk of dying compared with women aged 45-49 years at diagnosis. Figure 1illustrates the relative risk of dying among those women receiving no adjuvant treatment (equal to DBCG low-risk patients) and those receiving adjuvant cytotoxic treatment ( Figure 1) . The negative effect of young age is almost exclusively found in women diagnosed with low-risk disease not receiving adjuvant treatment, whereas no obvious negative effect of young age is seen among women receiving adjuvant cytotoxic treatment (8).
DISCUSSION
Most cancers, including breast cancer, are in their origin believed to be monoclonal diseases, meaning that tumours develop from basically one cancer cell that through numerous divisions grows into ac linically detectable mass. It has been estimated that a tumour with aw eight of one gram includes about 10 9 cells. When the tumour burden is around 10 12 cancer cells equivalent to about one kilogram of tumour mass, the disease is likely to be fatal (11) . Based on this assumption, models for disease progression can be investigated. Figure 2A illustrates as cenario with similar progression for three disease events. They start at the age 20 years, 40 years, and 60 years, respectively, and become detectable at aweight of one gram at the age of 40 years, 60 years, and 80 years, respectively. With continuous progression, the patients will die ten years after diagnosis. Nevertheless, the youngest woman has the highest risk of dying from cancer because the older woman has ah igher likelihood of dying from other causes before death due to breast cancer. However, if different cancers have different growth rates, the scenario could be as presented in Figure 2B . This figure illustrates three different diseases all starting at the age of 25 years. The rapidly growing disease will become detectable at ay oung age, whereas the disease with the slowest growth rate may never be detected. Rapidly growing tumours could theoretically develop at all ages, but among young patients only tumours with rapid growth rates would be expected to be detected. If this is at rue model for breast cancer, young age at diagnosis is an indicator for ar apidly growing and therefore more malignant disease. According to most studies, young age at diagnosis is associated with ap oor outcome. This is partly explained by disease in young patients being more aggressive and advanced, ap henomenon which would concur with the above illustrated tumour model. However, the majority of studies conclude that even after having adjusted for the effect of other prognostic factors, young age below 30-35 years remains an independent risk factor. Only one study (12) investigated the prognosis among extremely young patients aged 25 years or below at diagnosis. They found that their prognosis were in line with patients aged 26-35 years at diagnosis. Several observations suggest that breast cancer in young women behave differently compared with breast cancer in middle-aged and elderly women. Hereditary breast cancer is associated with young age at diagnosis. Mutations in the BRCA1 and BRCA2 genes are believed to be responsible for around 90 % of hereditary cases of breast cancer. Patients who are carriers of BRCA1 or BRCA2 mutations are more likely to present with tumours with high grades of malignancy compared to age-matched controls. It is controversial whether these mutations represent independent negative prognostic factors. However, in groups of young breast cancer patients not selected on the basis of afamiliar history of breast cancer, the overall proportion of BRCA1 and BRCA2 carriers is limited. Studies on unselected women diagnosed with breast cancer before the age of 35 years have found BRCA1 or BRCA2 mutations in only about 6% of the patients. Hence, BRCA1 and BRCA2 associated breast cancers is unlikely to be the only explanation for the particularly poor prognosis among the total group of young breast cancer patients.
An alternative explanation has been that aproportion of young patients could have been operated in an unfavourable period of the menstrual cycle which might lead to an inferior outcome. It is an open question whether such ar elation between surgical timing in the menstrual cycle and prognosis exist (13) .
Even if such an effect should exist, this hypothesis could not explain why women less than 35 years are doing significantly worse than women in their forties who continue having periods for on average of ten years.
ADJUVANT TREATMENT IN YOUNG BREAST CANCER PATIENTS
Accepting that young age at diagnosis is associated with an impaired prognosis raises the question whether these women would benefit from increased use of adjuvant treatment. Henderson and Patek (14) have argued against accepting young age alone as a criterion for adjuvant treatment. The International Consensus Panel on Treatment of Primary Breast Cancer has challenged this view. In 1995 it was stated that young age alone could not serve as asole criterion for giving adjuvant treatment. However, since 1998 the recommendation was changed to offer adjuvant treatment to all women below the age of 35 years at diagnosis (15) . It should be acknowledged that the result of the Danish study (8) only indirectly can be taken as evidence that young patients classified today according to the classical prognostic factors as having low-risk disease will benefit from adjuvant treatment in line with young patients diagnosed with high-risk disease. It has been shown that women classified with low-risk disease according to the classical prognostic factors do benefit from adjuvant cytotoxic treatment, and that the most pronounced positive effect is observed in premenopausal women. However, it remains to be demonstrated whether this also relates to young patients less than 35 years with high risk of recurrence and death despite afavourable prognostic profile.
In conclusion, young age at diagnosis of breast cancer should be regarded as acriterion for offering adjuvant systemic treatment. Further investigation is needed to identify the biological reasons for the impaired prognosis related to young age and to find the optimal treatment modality for this subset of breast cancer patients.
